Program
LT3001
A development code. Also written as “LT3001 Drug Product”, “LT3001 Drug:high dose” and “LT3001 Drug: low dose”.
Its studies are mostly in Ischemic Stroke, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lumosa Therapeutics | 52 open or running | phase 2since Sep 5, 2019 | Sep 5, 2019 | Dec 31, 2026phase 2 · NCT05198323 |
| Shanghai Pharmaceuticals | 22 open or running | phase 2since Jan 9, 2023 | Jan 9, 2023 | Dec 10, 2026phase 2 · NCT05686642 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 5, 2019First study: phase 2 study in Ischemic StrokeNew to Lumosa TherapeuticsLumosa Therapeutics · NCT04091945 · 24 enrolled · United States, Taiwan
- Mar 5, 2021Phase 1 study in Ischemic StrokeLumosa Therapeutics · NCT04809818 · 65 enrolled · United States
- Jan 3, 2022Phase 2 study in Ischemic StrokeLumosa Therapeutics · NCT05198323 · 66 enrolled · United States, Taiwan
- May 31, 2022Phase 2 study in Ischemic StrokeLumosa Therapeutics · NCT05403866 · 89 enrolled · United States
- Jan 9, 2023Shanghai Pharmaceuticals's first study: phase 2 study in Ischemic StrokeNew to Shanghai PharmaceuticalsShanghai Pharmaceuticals · NCT05686642 · 300 planned · China
- Aug 5, 2026Phase 2 study in Ischemic StrokeShanghai Pharmaceuticals · NCT07754825 · 300 planned · China
- Oct 16, 2026Phase 2 study in Ischemic StrokeLumosa Therapeutics · NCT07890298 · 10 planned · Taiwan
Ahead
- Dec 10, 2026Primary completion: phase 2 study in Ischemic StrokeShanghai Pharmaceuticals · NCT05686642
- Dec 31, 2026Primary completion: phase 2 study in Ischemic StrokeLumosa Therapeutics · NCT05198323
- Dec 31, 2027Primary completion: phase 2 study in Ischemic StrokeLumosa Therapeutics · NCT07890298
- Dec 31, 2027Primary completion: phase 2 study in Ischemic StrokeShanghai Pharmaceuticals · NCT07754825
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07890298Ischemic Stroke · Taiwan | 2 | Recruiting | Lumosa Therapeutics | Dec 31, 2027 | 10 |
| NCT07754825Ischemic Stroke · China | 2 | Not yet recruiting | Shanghai Pharmaceuticals | Dec 31, 2027 | 300 |
| NCT05686642Ischemic Stroke · China | 2 | Recruiting | Shanghai Pharmaceuticals | Dec 10, 2026 | 300 |
| NCT05403866Ischemic Stroke · United States | 2 | Completed | Lumosa Therapeutics | May 23, 2025 | 89 |
| NCT05198323Ischemic Stroke · United States, Taiwan | 2 | Active, not recruiting | Lumosa Therapeutics | Dec 31, 2026 | 66 |
| NCT04809818Ischemic Stroke · United States | 1 | Completed | Lumosa Therapeutics | Aug 5, 2021 | 65 |
| NCT04091945Ischemic Stroke · United States, Taiwan | 2 | Completed | Lumosa Therapeutics | Feb 22, 2021 | 24 |
How it is read
Names in the registry
- “LT3001 Drug Product”, 4 entries
- “LT3001 Drug:high dose”, 2 entries
- “LT3001 Drug: low dose”, 1 entry
- “LT3001 Drug:low dose”, 1 entry
- “LT3001 drug product”, 1 entry
Codes read as this program: LT3001.
Conditions, from the studies’ own filings
- Ischemic Stroke, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.